The partnership is mutually beneficial. Gata leverages Soonchain’s DePIN for computational power while Soonchain gamers monetize their contributions.The partnership is mutually beneficial. Gata leverages Soonchain’s DePIN for computational power while Soonchain gamers monetize their contributions.

Gata Partners with Soonchain to Advance Decentralized AI Development Through DePIN and Compute

blockchain main

Gata, a firm developing decentralized AI language models and training, announced a strategic collaboration with Soonchain AI, an AI-powered gaming Layer-2 network that infuses DePIN, AI, and GPU computations to provide effective, scalable solutions. Through this partnership, Gata integrated Soonchain’s DePIN technology to power its execution infrastructure for AI. The collaboration is beneficial for the two projects.

AI requires huge computing resources for training, testing, and deployment. However, this computing power is controlled by a few big centralized providers, making access to quality AI models expensive, complicated, and unavailable to smaller projects and ordinary users. Gata is which is built on BNB Chain, aims to address these challenges by developing affordable and quality decentralized AI accessible for global users.

Gata Driving Decentralized AI Innovation through Soonchain’s DePIN

Through this partnership, Soonchain’s DePIN provides an essential data layer for Gata’s variety of technological applications, which aim to provide the advantages of decentralized AI directly to people while making AI globally accessible. By integrating its AI infrastructure on Soonchain’s distributed network of GPUs, Gata resolves expensive data access costs that have hindered the decentralized AI advancement. This integration enables Gata to provide high-quality AI training and improve its decentralized infrastructure of AI advancement.

As Gata’s decentralized AI network expands, the demand for its infrastructure surges due to the increased need for quality datasets and reliable computation across its systems. Traditional data centres cannot meet these demands without introducing opaqueness and rigidness. This explains the reason Gata’s partnership with Soonchain’s DePIN is important for its AI operations.

The DePIN network shares processing power and energy usage across the world in a decentralized manner by taking advantage of idle data from personal computers owned by Soonchain gamers worldwide. The network of Soonchain’s gamers across the world and their devices contribute to Gata’s AI operations.

Why This Collaboration is Vital for Web3 Growth

Through this partnership, Soonchain’s DePIN is a perfect fit for Gata. Together, the two decentralized platforms resolve computational and data challenges through:

  • Advancing Gata’s AI performance and effectiveness. Gata’s AI requires huge computational power. Soonchain’s DePIN provides decentralized and scalable resources, which enable Gata’s rapid AI training and efficient alignment with its user demands.
  • Creating mutual advantage: Through its native token (GATA), Gata rewards Soonchain’s gamers for contributing their data and idle resources, creating a cycle where both contributors and providers (Gata and Soonchain) economically benefit.

By combining Gata’s AI infrastructure with Soonchain’s computational layer, the two platforms are creating a new standard for Web3 and AI: democratizing AI resources while empowering Web3 users.

Market Opportunity
Gata Logo
Gata Price(GATA)
$0.00435
$0.00435$0.00435
-7.85%
USD
Gata (GATA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26